Changes in Beneficial Ownership · 4
ZOETIS INC.
ZTSNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1784065683.xml
Filing details
- Report period
- 2026-07-10
- Issuer
- Zoetis Inc.
- Issuer CIK
- 0001555280
- Trading symbol
- ZTS
Reporting owner 1
- Name
- PECK KRISTIN C
- Reporting owner CIK
- 0001488267
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY, NJ, 07054
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phantom Stock Unit[F1] | [F2] | 2026-07-10 | A · Form 4 | 616.0892 | A | 26.22 | [F1] | [F1] | Common Stock | 213.7885 | 66,194.8959 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.↩ 1↩ 2↩ 3
- F2
- Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit). Accordingly, the value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.↩ 1
Signature 1
- Signed
- /s/ Brenda Santuccio, as Attorney-in-Fact
- Date
- 2026-07-14
Company context
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
Current securities
Recent company filings
- 4 filingOct 13, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 13, 2026
- Regulation FD DisclosureOct 8, 2026
- 4 filingAug 11, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 6, 2026